M
Marco Massari
Researcher at Istituto Superiore di Sanità
Publications - 127
Citations - 9676
Marco Massari is an academic researcher from Istituto Superiore di Sanità. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 35, co-authored 104 publications receiving 7903 citations. Previous affiliations of Marco Massari include Academy for Urban School Leadership & Santa Maria Nuova Hospital.
Papers
More filters
Journal ArticleDOI
Social contacts and mixing patterns relevant to the spread of infectious diseases.
Joël Mossong,Niel Hens,Mark Jit,Philippe Beutels,Kari Auranen,Rafael T. Mikolajczyk,Marco Massari,Stefania Salmaso,Gianpaolo Scalia Tomba,Jacco Wallinga,Janneke C. M. Heijne,Malgorzata Sadkowska-Todys,Magdalena Rosinska,W. John Edmunds +13 more
TL;DR: This study provides the first large-scale quantitative approach to contact patterns relevant for infections transmitted by the respiratory or close-contact route, and the results should lead to improved parameterisation of mathematical models used to design control strategies.
Journal ArticleDOI
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi,Marianna Meschiari,Alessandro Cozzi-Lepri,Jovana Milic,Roberto Tonelli,Marianna Menozzi,Erica Franceschini,Gianluca Cuomo,Gabriella Orlando,Vanni Borghi,Antonella Santoro,Margherita Di Gaetano,Cinzia Puzzolante,Federica Carli,Andrea Bedini,Luca Corradi,Riccardo Fantini,Ivana Castaniere,Luca Tabbì,Massimo Girardis,Sara K. Tedeschi,Maddalena Giannella,Michele Bartoletti,Renato Pascale,Giovanni Dolci,Lucio Brugioni,Antonello Pietrangelo,Andrea Cossarizza,Federico Pea,Enrico Clini,Carlo Salvarani,Marco Massari,Pierluigi Viale,Cristina Mussini +33 more
TL;DR: Assessment of the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment found it to be associated with a reduced risk.
Journal ArticleDOI
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
Gabriele Missale,Roberto Bertoni,Vincenzo Lamonaca,A Valli,Marco Massari,Cristina Mori,Maria Grazia Rumi,Michael Houghton,Franco Fiaccadori,Carlo Ferrari +9 more
TL;DR: Responses to all hepatitis C virus antigens were significantly more vigorous and more frequently detectable in patients who normalized transaminase levels than in those who did not, suggesting that the vigor of the T cell response during the early stages of infection may be a critical determinant of disease resolution and control.
Journal ArticleDOI
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Carlo Salvarani,Giovanni Dolci,Marco Massari,Domenico Franco Merlo,Silvio Cavuto,Luisa Savoldi,Paolo Bruzzi,Fabrizio Boni,Luca Braglia,Caterina Turrà,Pier Ferruccio Ballerini,Roberto Sciascia,Lorenzo Zammarchi,Ombretta Para,Pier Giorgio Scotton,Walter O Inojosa,Viviana Ravagnani,Nicola Duccio Salerno,Pier Paolo Sainaghi,Alessandro Brignone,Mauro Codeluppi,Elisabetta Teopompi,Maurizio Milesi,Perla Bertomoro,Norbiato Claudio,Mario Salio,Marco Falcone,Marco Falcone,Giovanni Cenderello,Lorenzo Donghi,Valerio Del Bono,Paolo Luigi Colombelli,Andrea Angheben,Angelina Passaro,Giovanni Secondo,Renato Pascale,Ilaria Piazza,Nicola Facciolongo,Massimo Costantini +38 more
TL;DR: This randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao2/Fio2 ratio between 200 and 300 mm Hg who received tocilizumab found no benefit on disease progression was observed compared with standard care, and further blinded, placebo-controlled randomized clinical trials are needed.
Journal ArticleDOI
PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion
Simona Urbani,Barbara Amadei,D. Tola,Marco Massari,Simona Schivazappa,Gabriele Missale,Carlo Ferrari +6 more
TL;DR: PD-1 expression declined with the acquisition of a memory phenotype and recovery of an efficient CD8 cell function in resolving HCV infections, whereas high levels were maintained when HCV persisted and HCV-specific CD8 cells remained dysfunctional.